Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 2, 2012, Pages 191-203

  Saremi, Adonis ^a   Gopal, Dipika ^b   Maisel, Alan S ^c  

^a UCSD MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Biomarkers; BNP; Guided therapy; Heart failure; Inpatient; Natriuretic peptides; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BISOPROLOL; BRAIN PEPTIDE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR C; SPIRONOLACTONE; VALSARTAN; VASOPRESSIN;

ACUTE HEART FAILURE; ALGORITHM; CENTRAL VENOUS PRESSURE; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; ENDOCYTOSIS; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HUMAN; META ANALYSIS (TOPIC); MITRAL VALVE STENOSIS; NATRIURESIS; OUTPATIENT CARE; PROTEIN METABOLISM; REVIEW; SYSTOLIC HEART FAILURE; VASODILATATION;

ALGORITHMS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; INPATIENTS; NATRIURETIC PEPTIDE, BRAIN; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84856615848     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.188     Document Type: Review

References (65)

1. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics: 2011 update: a report from the American Heart Association. Circulation 123(4), e18-e209 (2011).
2. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur. Heart J. 12, 315-321 (1991).
3. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261, 884-888 (1989). (Pubitemid 19046417)
4. Atkinson A, Colburn W, DeGruttola V et al. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001). (Pubitemid 32225406)
5. Bozkurt B, Mann DL. Use of biomarkers in the management of heart failure. Are we there yet? Circulation 107, 1231-1233 (2003). (Pubitemid 36314401)
6. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115, 949-952 (2007). (Pubitemid 46328287)
7. Clerico A, Vittorini S, Passino C, Emdin M. New and emerging biomarkers of heart failure. Crit. Rev. Clin. Lab. Sci. 46, 107-128 (2009).
8. Jortani SA, Prabhu SD, Valdes R. Strategies for developing biomarkers of heart failure. Clin. Chem. 50, 265-278 (2004). (Pubitemid 38156366)
9. Taub PR, Gabbai-Saldate P, Maisel A. Biomarkers of heart failure. Congest. Heart Fail. 16(1 Suppl.), S19-S24 (2010).
10. Novo G, Amoroso GR, Fazio G et al. Biomarkers in heart failure. Front. Biosci. 14, 2484-2493 (2009).
11. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am. J. Physiol. Heart Circ. Physiol. 301, H12-H20 (2011).
12. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J. Cardiol. 57, 131-140 (2011).
13. Emdin M, Passino C, Clerico A. Natriuretic peptide assays revisited. Do we need proB-type natriuretic peptide? J. Am. Coll. Cardiol. 57, 1396-1398 (2011).
14. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007 (1999).
15. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 353, 9-13 (1999).
16. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).N. Engl. J. Med. 316, 1429-1435 (1987).
17. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991).
18. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717 (1999). (Pubitemid 29407370)
19. Lenzen MJ, Boersma E, Reimer WJ et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur. Heart J. 26, 2706-2713 (2005). (Pubitemid 41748284)
20. Hauptman PJ, Swindle JP, Masoudi FA, Burroughs TE. Underutilization of beta-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures. Circ. Cardiovasc. Qual. Outcomes 3, 204-211 (2010).
21. Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Thanapiboonpol P, Nakyen S, Udompunturak S. Correlation between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. J. Card. Fail. 14, 687-694 (2008).
22. Haug C, Metzele A, Kochs M, Hombach V, Granert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin. Cardiol. 16, 553-557 (1993). (Pubitemid 23196931)
23. Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br. Heart J. 69, 414-417 (1993). (Pubitemid 23171117)
24. Yoshimura M, Yasue H, Okumura K et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87, 464-469 (1993). (Pubitemid 23040916)
25. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 37, 1228-1233 (2001).
26. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 100, 1056-1064 (1999). (Pubitemid 29416231)
27. Latini R, Masson S, Anand I et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Val-HeFT trial. Circulation 106, 2454-2458 (2002). (Pubitemid 35278801)
28. Troughton RW, Richards AM, Yandle TG, Frampton CM, Nicholls MG. The effects of medications on circulating levels of cardiac natriuretic peptides. Ann. Med. 39, 242-260 (2007). (Pubitemid 46897664)
29. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347, 161-167 (2002). (Pubitemid 34764819)
30. Maisel A, Hollander JE, Guss D et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J. Am. Coll. Cardiol. 44, 1328-1333 (2004). (Pubitemid 39208893)
31. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J. Am. Coll. Cardiol. 49, 1943-1950 (2007). (Pubitemid 46694287)
32. Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 115, 3103-3110 (2007). (Pubitemid 46956499)
33. Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med. 350, 647-654 (2004). (Pubitemid 38364623)
34. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130 (2000). (Pubitemid 30172933)
35. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J. Am. Coll. Cardiol. 49, 1733-1739 (2007). (Pubitemid 46589928)
36. Berger R, Moertl D, Peter S et al. N-terminal pro-B-type natriuretic peptide-guided intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J. Am. Coll. Cardiol. 55, 645-653 (2010).
37. Felker GM, Hasselblad V, Hernandez AF et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am. Heart J. 158, 422-430 (2009).
38. Lainchbury JG, Troughton RW, Strangman KM et al. N-terminal pro-B-type natriuretic peptide-guided treatment of chronic heart failure. J. Am. Coll. Cardiol. 55, 53-60 (2010).
39. Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch. Intern. Med. 170, 507-514 (2010).
40. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H. BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. Congest. Heart Fail. 11, 248-253 (2005).
41. Shah MR, Califf RM, Nohria A et al. STARBRITE: a randomized pilot trial of BNP-guided therapy in patients with advanced heart failure. Presented at: American Heart Association Scientific Sessions. Chicago, IL, USA, 12-15 November 2006.
42. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlstrom U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NTproBNP-Guided Management of Heart Failure-SIGNALHF (Swedish Intervention study - Guidelines and NTproBNP Analysis in Heart Failure). Eur. J. Heart Fail. 12, 1300-1308 (2010).
43. Pfisterer MP, Buser P, Rickli H et al.; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301, 383-392 (2009).
44. Eurlings LW, van Pol PE, Kok WE et al. Management of chronic heart failure guided by individual N-terminal pro-Btype natriuretic peptide targets: results of the PRIMA (Can Pro-Brain-Natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?) study. J. Am. Coll. Cardiol. 56, 2090-2100 (2010).
45. Clerico A, Fontana M, Ripoli A et al. Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. Adv. Clin. Chem. 48, 163-179 (2009).
46. Bayes-Genis A, Santalo-Bel M, Zapico- Muniz E et al. N-terminal probrain natriuretic peptide (NTproBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur. J. Heart Fail. 6, 301-308 (2004). (Pubitemid 38253049)
47. Di Somma S, Magrini L, Mazzone M et al. Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure. Am. J. Emerg. Med. 25, 335-339 (2007). (Pubitemid 46356860)
48. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminalpro- brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110, 2168-2174 (2004). (Pubitemid 39372496)
49. Bayes-Genis A, Lopez L, Zapico E et al. NTproBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J. Card. Fail. 11(Suppl. 5), S3-S8 (2005).
50. Cournot M, Leprince P, Destrac S et al. Usefulness of in-hospital change in B-type natriuretic peptide levels in predicting long-term outcome in elderly patients admitted for decompensated heart failure. Am. J. Geriatr. Cardiol. 16(1), 8-14 (2007).
51. Logeart D, Thabut G, Jourdain P et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol. 43, 635-641 (2004). (Pubitemid 38229537)
52. Valle R, Aspromonte N, Giovinazzo P et al. B-type natriuretic peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure. J. Cardiac Fail. 14, 219-224 (2008). (Pubitemid 351444865)
53. Noveanu M, Breidthardt T, Potocki M et al. Direct comparison of serial B-type natriuretic peptide and NTproBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure. Crit. Care 15(1), R1 (2011).
54. Cournot M, Mourre F, Castel F et al. Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure. Am. Heart J. 155(6), 986-991 (2008).
55. Di Somma S, Magrini L, Pittoni V et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED study. Crit. Care 14(3), R116 (2010).
56. Bettencourt P, Januzzi J. Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure. Am. J. Cardiol. 101(1), A67-A71 (2008).
57. Xue Y, Chan J, Sakariya S et al. Biomarkerguided treatment of congestive heart failure. Congest. Heart Fail. 16(4 Suppl. 1), S62-S67 (2010).
58. Emdin M, Vittorini S, Passino C et al. Old and new biomarkers of heart failure. Eur. J. Heart Fail. 11, 331-335 (2009).
59. Yin WH, Chen JW, Feng AN et al. Multimarker approach to risk stratification among patients with advanced chronic heart failure. Clin. Cardiol. 30, 397-402 (2007).
60. Ishino M, Takeishi Y, Niizeki T, Watanabe T, Nitobe J, Miyamoto T. Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3. Circ. J. 72, 1800-1805 (2008).
61. Niizeki T, Takeishi Y, Kitahara T et al. Combination of conventional biomarkers for risk stratification in chronic heart failure. J. Cardiol. 53, 179-187 (2009).
62. Tziakas D, Chalikias G, Stakos D et al. Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. Eur. J. Cardiovasc. Prev. Rehabil. doi:10.1097/HJR.0b013e32833ace76 (2010) (Epub ahead of print).
63. Volpe M, Francia P, Tocci G et al. Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study. Clin. Cardiol. 33, 700-707 (2010).
64. Tang WH, Shrestha K, Troughton RW, Borowski AG, Klein AL. Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure. Congest. Heart Fail. 17, 105-109 (2011).
65. Gopal DJ, Iqbal MN, Maisel A. Updating the role of natriuretic peptide levels in cardiovascular disease. Postgrad. Med. 123(6), 102-113 (2011).